New Diagnostic Test for Pancreatic Cancer Is Based on the Differential Expression of Select miRNAs in Plasma and Bile
|
By LabMedica International staff writers Posted on 10 Nov 2014 |
|
A panel of microRNA (miRNA) biomarkers was assembled from the pool of miRNAs present in the blood of most pancreatic cancer patients that may serve as a diagnostic tool and an indicator of the disease’s aggressiveness.
Pancreatic cancer is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with one- and five-year survival rates of only 20% and 6%, respectively. Therefore, markers of the disease that could help with early diagnosis are needed to improve the prognosis. Statistics from the [US] National Cancer Institute (Bethesda, MD, USA) show that only about 6% of people with pancreatic cancer survive more than five years after diagnosis. In 2013 an estimated 45,220 new cases of pancreatic cancer were expected to be diagnosed with more than 38,460 of the cases being fatal.
MiRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
Investigators at Indiana University (Indianapolis, USA) determined miRNA levels in blood or bile obtained from 215 patients with pancreatic ductal adenocarcinoma (PDAC) or from controls. Panels were derived from the differential expression of 10 candidate miRNAs in the samples. MiRNAs that had excellent accuracy for inclusion in regression models were selected. Total RNA was isolated from samples using Trizol-LS (Life Technologies; Carlsbad, CA, USA). Complementary DNA was generated using 10 ng of RNA in conjunction with miRNA-10b, -21, -30c, -106b, -132, -155, -181a, -181b, -196a, -212, or -425-5p reverse transcription primers and a miRNA reverse transcription kit (Life Technologies). Quantitative PCR was performed for each miRNA using Taqman (Life Technologies) miRNA expression assay reagents.
Results revealed that increased expression of miRNA-10b, -155, and -106b in plasma appeared to be highly accurate for diagnosing pancreatic cancer.
Senior author Dr. Murray Korc, professor of cancer research at Indiana University, said, “This is a new finding that extends previous knowledge in this field. The key new feature here is that there is a panel of microRNAs that can be measured accurately in the plasma component of blood to determine if a patient has pancreatic cancer. It may be possible to use a blood test to screen individuals who are at high risk for developing pancreatic cancer. We are planning to conduct such studies. It will be important to identify additional markers and to assess how useful a panel of such markers would be for the early diagnosis of this cancer. Based on our findings, this test could also be useful to differentiate between pancreatic cancer and chronic pancreatitis.”
The study was published in the October 28, 2014, online edition of the American Journal of Gastroenterology.
Related Links:
National Cancer Institute
Indiana University
Life Technologies
Pancreatic cancer is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with one- and five-year survival rates of only 20% and 6%, respectively. Therefore, markers of the disease that could help with early diagnosis are needed to improve the prognosis. Statistics from the [US] National Cancer Institute (Bethesda, MD, USA) show that only about 6% of people with pancreatic cancer survive more than five years after diagnosis. In 2013 an estimated 45,220 new cases of pancreatic cancer were expected to be diagnosed with more than 38,460 of the cases being fatal.
MiRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
Investigators at Indiana University (Indianapolis, USA) determined miRNA levels in blood or bile obtained from 215 patients with pancreatic ductal adenocarcinoma (PDAC) or from controls. Panels were derived from the differential expression of 10 candidate miRNAs in the samples. MiRNAs that had excellent accuracy for inclusion in regression models were selected. Total RNA was isolated from samples using Trizol-LS (Life Technologies; Carlsbad, CA, USA). Complementary DNA was generated using 10 ng of RNA in conjunction with miRNA-10b, -21, -30c, -106b, -132, -155, -181a, -181b, -196a, -212, or -425-5p reverse transcription primers and a miRNA reverse transcription kit (Life Technologies). Quantitative PCR was performed for each miRNA using Taqman (Life Technologies) miRNA expression assay reagents.
Results revealed that increased expression of miRNA-10b, -155, and -106b in plasma appeared to be highly accurate for diagnosing pancreatic cancer.
Senior author Dr. Murray Korc, professor of cancer research at Indiana University, said, “This is a new finding that extends previous knowledge in this field. The key new feature here is that there is a panel of microRNAs that can be measured accurately in the plasma component of blood to determine if a patient has pancreatic cancer. It may be possible to use a blood test to screen individuals who are at high risk for developing pancreatic cancer. We are planning to conduct such studies. It will be important to identify additional markers and to assess how useful a panel of such markers would be for the early diagnosis of this cancer. Based on our findings, this test could also be useful to differentiate between pancreatic cancer and chronic pancreatitis.”
The study was published in the October 28, 2014, online edition of the American Journal of Gastroenterology.
Related Links:
National Cancer Institute
Indiana University
Life Technologies
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
POC Immunoassay Analyzer
Procise DX
Automated Urinalysis Solution
UN-9000
Latest Pathology News
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
- CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
- Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
- AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
- Hybrid Computational Imaging Method Improves Digital Pathology Resolution
- FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Channels
Clinical Chemistry
view channel
Blood Protein Panel Supports Monitoring of Treated Celiac Disease
Celiac disease is an autoimmune condition in which gluten triggers intestinal inflammation that can damage the gut and impair nutrient absorption. Even with a gluten-free diet, some patients may continue... Read more
Hemoglobin Levels May Help Signal Long-Term Dementia Risk
Dementia is a growing health challenge in aging societies, with limited treatment options and no cure. Identifying long-term risk remains difficult, particularly when specialist scans or emerging biomarkers... Read more
Molecular Diagnostics
view channel
Study Shows How Genome Reference Bias Can Mislead Preventive Testing
Whole-genome sequencing is expected to play a growing role in preventive and predictive medicine, but accurate interpretation remains a major diagnostic challenge. The approach requires comparing billions... Read more
Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer
For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
Chronological age does not always reflect immune health or future disease risk. Two adults of the same age can have immune systems that age very differently, with some remaining resilient while others... Read more
Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
Lung cancer remains difficult to detect before symptoms appear, when advanced disease is harder to treat. In the U.K., about 32,800 people die from lung cancer each year, and only 11.1% of those diagnosed... Read more
Microbiology
view channel
Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
Long Covid can involve persistent respiratory, cognitive, and gastrointestinal symptoms after acute infection, creating a difficult diagnostic and management challenge. Because COVID-19 initially affects... Read more
Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
Malaria remains one of the world’s deadliest infectious diseases and has affected humans throughout recorded history. In regions where malaria is common, human genetics have been shaped by the sickle cell... Read more
Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more
Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read moreTechnology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation
Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing
Estrogen receptor-positive (ER+), HER2-negative advanced breast cancer may require molecular testing to guide treatment selection, with blood-based assays offering a way to identify tumor mutations that... Read more
